MX2019014310A - Agente para prevenir o tratar atrofia cerebral. - Google Patents
Agente para prevenir o tratar atrofia cerebral.Info
- Publication number
- MX2019014310A MX2019014310A MX2019014310A MX2019014310A MX2019014310A MX 2019014310 A MX2019014310 A MX 2019014310A MX 2019014310 A MX2019014310 A MX 2019014310A MX 2019014310 A MX2019014310 A MX 2019014310A MX 2019014310 A MX2019014310 A MX 2019014310A
- Authority
- MX
- Mexico
- Prior art keywords
- brain atrophy
- agent
- preventing
- suppressing
- treating brain
- Prior art date
Links
- 208000024806 Brain atrophy Diseases 0.000 title abstract 4
- HQNACSFBDBYLJP-UHFFFAOYSA-N 1-[3-[2-(1-benzothiophen-5-yl)ethoxy]propyl]azetidin-3-ol Chemical compound C1C(O)CN1CCCOCCC1=CC=C(SC=C2)C2=C1 HQNACSFBDBYLJP-UHFFFAOYSA-N 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 230000032683 aging Effects 0.000 abstract 1
- 239000013043 chemical agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se dirige al problema de proporcionar un agente químico para suprimir la progresión de la demencia del tipo de Alzheimer y un método para suprimir la progresión de la demencia del tipo de Alzheimer. El 1-(3-(2-(1-benzotiofen-5-il)eto xi)propil)azetidin-3-ol o una sal del mismo tiene un efecto de supresión de la atrofia cerebral, y es útil como un agente profiláctico o terapéutico para la atrofia cerebral. Por consiguiente, es posible prevenir o tratar la atrofia cerebral observada en el proceso de envejecimiento o en las enfermedades neurodegenerativas por medio de la administración del 1-(3-(2-(1-benzotiofen-5-il)etoxi)propil)azetidin-3-ol o una sal del mismo.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017109885 | 2017-06-02 | ||
JP2017128472 | 2017-06-30 | ||
JP2017145100 | 2017-07-27 | ||
PCT/JP2018/021223 WO2018221729A1 (ja) | 2017-06-02 | 2018-06-01 | 脳萎縮予防または治療剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019014310A true MX2019014310A (es) | 2022-06-10 |
Family
ID=64455855
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019014310A MX2019014310A (es) | 2017-06-02 | 2018-06-01 | Agente para prevenir o tratar atrofia cerebral. |
Country Status (15)
Country | Link |
---|---|
US (1) | US11951092B2 (es) |
EP (1) | EP3632431A4 (es) |
JP (2) | JP7282028B2 (es) |
KR (1) | KR20190137936A (es) |
CN (3) | CN116473962A (es) |
AU (1) | AU2018276638B2 (es) |
BR (1) | BR112019024851A2 (es) |
CA (1) | CA3067453C (es) |
IL (1) | IL270922A (es) |
MX (1) | MX2019014310A (es) |
NZ (1) | NZ759585A (es) |
RU (1) | RU2759727C2 (es) |
SG (1) | SG11201911512SA (es) |
WO (1) | WO2018221729A1 (es) |
ZA (1) | ZA201907973B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3632430A4 (en) | 2017-06-02 | 2020-06-10 | FUJIFILM Toyama Chemical Co., Ltd. | AGENT FOR THE PREVENTION OR TREATMENT OF SPINOCEREBELLOUS ATAXIA |
JPWO2018221728A1 (ja) | 2017-06-02 | 2020-04-02 | 富士フイルム富山化学株式会社 | アルツハイマー型認知症予防または治療剤 |
KR20200003102A (ko) | 2017-06-02 | 2020-01-08 | 후지필름 도야마 케미컬 가부시키가이샤 | 아밀로이드 β 단백질량 감소제 |
BR112019024851A2 (pt) * | 2017-06-02 | 2020-06-09 | Fujifilm Toyama Chemical Co Ltd | agente para evitar ou tratar atrofia cerebral |
EP3705121B1 (en) | 2017-10-30 | 2023-08-30 | FUJIFILM Toyama Chemical Co., Ltd. | Emopamil binding protein binding agent and use thereof |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2302808C (en) | 1997-09-05 | 2010-05-18 | Human Genome Sciences, Inc. | 50 human secreted proteins |
GB9824207D0 (en) | 1998-11-04 | 1998-12-30 | Zeneca Ltd | Neurological disorders |
BRPI0213393B8 (pt) | 2001-10-19 | 2021-05-25 | Fujifilm Toyama Chemical Co Ltd | derivados de éter alquílico, ou um de seus sais, processo para produzir um derivado de éter alquílico, derivado de alquil-amida, ou um de seus sais, e, composição farmacêutica |
CN100375619C (zh) | 2002-06-14 | 2008-03-19 | 富山化学工业株式会社 | 改善脑功能的药物组合物及其用途 |
CA2521648C (en) | 2003-04-17 | 2012-07-03 | Toyama Chemical Co., Ltd. | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof |
US8119625B2 (en) * | 2006-04-26 | 2012-02-21 | Toyama Chemical Co., Ltd. | Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof |
MX2008013728A (es) | 2006-04-26 | 2009-01-07 | Toyama Chemical Co Ltd | Inductor de neurogenesis o agente terapeutico de neuropatia que abarca el derivado del eter alkilico o sal del mismo. |
AU2009220974B2 (en) | 2008-03-04 | 2013-10-24 | Vernalis (R&D) Ltd. | Azetidine derivatives |
FR2934596B1 (fr) | 2008-07-30 | 2015-04-10 | Trophos | Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation |
US8404711B2 (en) | 2009-04-13 | 2013-03-26 | Theravance, Inc. | 5-HT4 receptor agonist compounds for treatment of cognitive disorders |
CN102802620A (zh) | 2009-05-11 | 2012-11-28 | 英维沃医药有限公司 | 使用某种α-7烟酸受体与乙酰胆碱酯酶抑制剂结合治疗认知障碍 |
WO2011057199A1 (en) | 2009-11-06 | 2011-05-12 | Adenios, Inc. | Compositions for treating cns disorders |
TR201907882T4 (tr) | 2012-02-22 | 2019-06-21 | Fujifilm Toyama Chemical Co Ltd | 1-(3-(2-(1-Benzotiofen-5-il)etoksi)propil)azetidin-3-olü veya onun tuzunu içeren katı farmasötik bileşim |
AU2013292519B2 (en) | 2012-07-19 | 2017-12-07 | Drexel University | Sigma receptor ligands for modulating cellular protein homeostasis |
KR101676212B1 (ko) | 2012-10-01 | 2016-11-14 | 에프. 호프만-라 로슈 아게 | Cns 활성제로서 벤즈이미다졸 |
EP3100725B1 (en) | 2014-01-31 | 2020-05-06 | FUJIFILM Toyama Chemical Co., Ltd. | Post nerve injury rehabilitation effect-enhancing agent comprising an alkyl ether derivative or a salt thereof |
US20170129915A1 (en) | 2014-04-25 | 2017-05-11 | Resilio Company Limited | Therapeutic agent for diseases associated with nerve axon dysfunction, including therapeutic agent for alzheimer's disease |
WO2015188368A1 (en) | 2014-06-13 | 2015-12-17 | Merck Sharp & Dohme Corp. | Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles |
WO2016051799A1 (ja) | 2014-10-01 | 2016-04-07 | 学校法人同志社 | 2-アミノヒドロキノン誘導体及びタウ凝集阻害剤 |
WO2016124508A1 (en) | 2015-02-02 | 2016-08-11 | Ucb Biopharma Sprl | 9h-pyrrolo-dipyridine derivatives |
US20160324851A1 (en) | 2015-05-07 | 2016-11-10 | Axovant Sciences, Ltd. | Methods of treating a neurodegenerative disease |
EP3308782B1 (en) | 2015-06-11 | 2022-01-19 | Toyama Chemical Co., Ltd. | Sigma-receptor binding agent |
DK3395342T3 (da) | 2015-12-25 | 2020-10-12 | Fujifilm Toyama Chemical Co Ltd | Tablet omfattende 1-(3-(2-(1-benzothiophen-5-YL)ethoxy)propyl)azetidin-3-ol eller salt deraf |
JPWO2018221728A1 (ja) | 2017-06-02 | 2020-04-02 | 富士フイルム富山化学株式会社 | アルツハイマー型認知症予防または治療剤 |
KR20200003102A (ko) | 2017-06-02 | 2020-01-08 | 후지필름 도야마 케미컬 가부시키가이샤 | 아밀로이드 β 단백질량 감소제 |
JP7370859B2 (ja) | 2017-06-02 | 2023-10-30 | 富士フイルム富山化学株式会社 | タウオパチー予防または治療剤 |
BR112019024851A2 (pt) * | 2017-06-02 | 2020-06-09 | Fujifilm Toyama Chemical Co Ltd | agente para evitar ou tratar atrofia cerebral |
EP3632430A4 (en) | 2017-06-02 | 2020-06-10 | FUJIFILM Toyama Chemical Co., Ltd. | AGENT FOR THE PREVENTION OR TREATMENT OF SPINOCEREBELLOUS ATAXIA |
EP3705121B1 (en) | 2017-10-30 | 2023-08-30 | FUJIFILM Toyama Chemical Co., Ltd. | Emopamil binding protein binding agent and use thereof |
-
2018
- 2018-06-01 BR BR112019024851A patent/BR112019024851A2/pt unknown
- 2018-06-01 AU AU2018276638A patent/AU2018276638B2/en active Active
- 2018-06-01 WO PCT/JP2018/021223 patent/WO2018221729A1/ja active Application Filing
- 2018-06-01 CA CA3067453A patent/CA3067453C/en active Active
- 2018-06-01 US US16/617,739 patent/US11951092B2/en active Active
- 2018-06-01 KR KR1020197035347A patent/KR20190137936A/ko not_active IP Right Cessation
- 2018-06-01 CN CN202310470444.0A patent/CN116473962A/zh active Pending
- 2018-06-01 NZ NZ759585A patent/NZ759585A/en unknown
- 2018-06-01 RU RU2019138166A patent/RU2759727C2/ru active
- 2018-06-01 CN CN201880035394.0A patent/CN110709078A/zh active Pending
- 2018-06-01 JP JP2019521348A patent/JP7282028B2/ja active Active
- 2018-06-01 MX MX2019014310A patent/MX2019014310A/es unknown
- 2018-06-01 CN CN202310474317.8A patent/CN116492335A/zh active Pending
- 2018-06-01 SG SG11201911512SA patent/SG11201911512SA/en unknown
- 2018-06-01 EP EP18810520.9A patent/EP3632431A4/en active Pending
-
2019
- 2019-11-25 IL IL270922A patent/IL270922A/en unknown
- 2019-11-29 ZA ZA2019/07973A patent/ZA201907973B/en unknown
-
2023
- 2023-02-15 JP JP2023021443A patent/JP2023053337A/ja not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
SG11201911512SA (en) | 2020-01-30 |
NZ759585A (en) | 2022-02-25 |
JP2023053337A (ja) | 2023-04-12 |
AU2018276638B2 (en) | 2021-04-08 |
WO2018221729A1 (ja) | 2018-12-06 |
CN110709078A (zh) | 2020-01-17 |
JPWO2018221729A1 (ja) | 2020-04-09 |
ZA201907973B (en) | 2022-03-30 |
RU2759727C2 (ru) | 2021-11-17 |
BR112019024851A2 (pt) | 2020-06-09 |
US11951092B2 (en) | 2024-04-09 |
RU2019138166A3 (es) | 2021-07-09 |
CN116473962A (zh) | 2023-07-25 |
RU2019138166A (ru) | 2021-07-09 |
CN116492335A (zh) | 2023-07-28 |
EP3632431A4 (en) | 2020-06-03 |
IL270922A (en) | 2020-01-30 |
AU2018276638A1 (en) | 2019-12-19 |
CA3067453A1 (en) | 2018-12-06 |
EP3632431A1 (en) | 2020-04-08 |
US20200215030A1 (en) | 2020-07-09 |
CA3067453C (en) | 2021-11-23 |
KR20190137936A (ko) | 2019-12-11 |
JP7282028B2 (ja) | 2023-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ759585A (en) | Agent for preventing or treating brain atrophy | |
MX2021010198A (es) | Indoles n-sustituidos y otros heterociclos para el tratamiento de trastornos cerebrales. | |
MX2021001903A (es) | Moduladores de regulador de conductancia transmembranal de fibrosis quistica. | |
MX2021010193A (es) | Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales. | |
MX2019014300A (es) | Agente para prevenir o tratar la tauopatia. | |
MX2020011528A (es) | Inhibidores heterociclicos sustituidos de ptpn11. | |
MX2020001732A (es) | Tratamiento de las afecciones del sistema nervioso central. | |
NZ760919A (en) | Compounds, compositions and methods for modulating eukaryotic initiation factor 2b | |
PH12016501600A1 (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
MX2020001757A (es) | Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades. | |
EA201890318A1 (ru) | СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ | |
TN2017000134A1 (en) | 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease | |
SG10201907699YA (en) | Substituted pyrazole compounds as serine protease inhibitors | |
EA201890256A1 (ru) | 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 | |
MX2020006237A (es) | Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4. | |
MX2019014306A (es) | Agente para reducir la cantidad de proteina beta amiloide. | |
EP3681477A4 (en) | IMPROVED METHOD AND COMPOSITION FOR THE TREATMENT OF CONDITIONS, DISEASES OR DISORDERS SENSITIVE TO TRITERPENES | |
NZ759647A (en) | Agent for preventing or treating spinocerebellar ataxia | |
WO2020021477A3 (en) | Compositions and methods for treating the eye | |
EP3263119A4 (en) | Composition including extracellular vesicles derived from bacteria of bacillus sp. for treating pregnancy-associated diseases | |
MX2017017171A (es) | Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias. | |
PH12019500198A1 (en) | Compounds and compositions and uses thereof | |
WO2017221237A8 (en) | Fungicidal compositions and methods for controlling plant pathogens | |
MX2018009662A (es) | Metodo y composicion farmaceutica para tratamiento de neurodegeneracion. | |
MX2018001592A (es) | Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos. |